Abstract:Background and purpose: Isocitrate dehydrogenase (IDH) mutation and 1p/19q codeletion classify adult-type diffuse gliomas into 3 tumor subtypes with distinct prognoses. We aimed to evaluate the performance of edited MR spectroscopy for glioma subtyping in a clinical setting, via the quantification of D-2-hydroxyglutarate (2HG) and cystathionine. The delay between this noninvasive classification and the integrated histomolecular analysis was also quantified. Materials and methods: Subjects with presumed low-grade gliomas eligible for surgery (cohort 1) and subjects with IDH-mutant gliomas previously treated and with progressive disease (cohort 2) were prospectively examined with a single-voxel Mescher-Garwood point-resolved spectroscopy sequence at 3T. Spectra were quantified using LCModel. The Cramér-Rao lower bounds threshold was set to 20%. Integrated histomolecular analysis according to the 2021 WHO classification was considered as ground truth. Results: Thirty-four consecutive subjects were enrolled. Due to poor spectra quality and lack of histologic specimens, data from 26 subjects were analyzed. Twenty-one belonged to cohort 1 (11 women; median age, 42 years); and 5, to cohort 2 (3 women; median age, 48 years). Edited MR spectroscopy showed 100% specificity for detection of IDH-mutation and 91% specificity for the prediction of 1p/19q-codeletion status. Sensitivities for the prediction of IDH and 1p/19q codeletion were 69% and 33%, respectively. The median Cramér-Rao lower bounds values were 16% (13%-28%) for IDH-mutant and 572% (554%-999%) for IDH wild type tumors. The time between MR spectroscopy and surgery was longer for low-grade than for high-grade gliomas (P = .03), yet the time between MR spectroscopy and WHO diagnosis did not differ between grades (P = .07), possibly reflecting molecular analyses-induced delays in high-grade gliomas. Conclusions: Our results, acquired in a clinic setting, confirmed that edited MR spectroscopy is highly specific for both IDH-mutation and 1p/19q-codeletion predictions and can provide a faster prognosis stratification. In the upcoming IDH-inhibitor treatment era, incorporation of edited MR spectroscopy into clinical workflow is desirable.

Absolute quantification of 2-hydroxyglutarate on tissue by matrix-assisted laser desorption/ionization mass spectrometry imaging for rapid and precise identification of isocitrate dehydrogenase mutations in human glioma

Rapid Diagnosis of IDH1-mutated Gliomas by 2-HG Detection with Gas Chromatography Mass Spectrometry.

Rapid Determination of Isocitrate Dehydrogenase Mutation Status of Human Gliomas by Extraction Nanoelectrospray Using a Miniature Mass Spectrometer

Rapid detection of IDH mutations in gliomas by intraoperative mass spectrometry

Detection of IDH mutation in glioma by desorption electrospray ionization (DESI) tandem mass spectrometry

Selective Detection of the D-Enantiomer of 2-Hydroxyglutarate in the Csf of Glioma Patients with Mutated Isocitrate Dehydrogenase

Predicting IDH mutation status as well as Ki-67 and p53 expression in high-grade gliomas using amide proton transfer-weighted and arterial spin labeling MRI

Detection of "oncometabolite" 2-Hydroxyglutarate by Magnetic Resonance Analysis As A Biomarker of Idh1/2 Mutations in Glioma

Comparative study of IDH1 mutations in gliomas by high resolution melting analysis, immunohistochemistry and direct DNA sequencing

Application of High Resolution Melting Analysis in Detecting IDH1 Mutation in Glioma Patients

Intraoperative detection of isocitrate dehydrogenase mutations in human gliomas using a miniature mass spectrometer

Preliminary Establishment of High Resolution Melting Analysis for Detecting IDH1 Gene Mutations in Gliomas

IDH1 Mutation Detection by Droplet Digital PCR in Glioma.

A biosensor for D-2-hydroxyglutarate in frozen sections and intraoperative assessment of IDH mutation status

The diagnostic efficiency of integration of 2HG MRS and IVIM versus individual parameters for predicting IDH mutation status in gliomas in clinical scenarios: A retrospective study

A high-throughput SAMDI-mass spectrometry assay for isocitrate dehydrogenase 1.

Noninvasive Idh1 Mutation Estimation Based on A Quantitative Radiomics Approach for Grade Ii Glioma

Incorporation of Edited MRS into Clinical Practice May Improve Care of Patients with IDH-Mutant Glioma

Single-cell profiling of D-2-hydroxyglutarate using surface-immobilized resazurin analogs

A genetically encoded fluorescent sensor enables sensitive and specific detection of IDH mutant associated oncometabolite D-2-hydroxyglutarate

Oncometabolite 2-HG in glioma evolution and recent progress of detection method